Inborn errors of metabolism:

Indications for OXLUMO:

Treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels.

Adults and Children:

Give by SC inj into abdomen, thigh, or upper arms; rotate inj sites. <10kg: loading dose: 6mg/kg once monthly for 3 doses; maintenance (begin 1 month after the last loading dose): 3mg/kg once monthly. 10–<20kg: loading dose: 6mg/kg once monthly for 3 doses; maintenance (begin 1 month after the last loading dose): 6mg/kg once every 3 months. ≥20kg: loading dose: 3mg/kg once monthly for 3 doses; maintenance (begin 1 month after the last loading dose): 3mg/kg once every 3 months.

OXLUMO Warnings/Precautions:

Severe hepatic impairment (total bilirubin >3×ULN with any AST), eGFR <30mL/min/1.73m2, or dialysis patients: not studied. Pregnancy. Nursing mothers.

OXLUMO Classification:

HAO1-directed small interfering ribonucleic acid.

Adverse Reactions:

Inj site reactions, abdominal pain.

Generic Drug Availability:

NO

How Supplied:

Single-dose vial—1

Pricing for OXLUMO

94.5mg/0.5ml vial (Qty: 1)
Appx. price $112209
GoodRx